Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase Marcus Maurer, MD, Sabine Altrichter, MD,

Slides:

Advertisements

Similar presentations

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Advertisements

Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial Annice Heratizadeh, MD, Thomas Werfel,

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,

Responsiveness and minimal important difference of the urticaria control test Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria Ragip Ertas, MD, Kemal Ozyurt,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Shyam Joshi, MD, David A. Khan, MD

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Patient perspectives on the management of atopic dermatitis

Is 9 more than 2 also in allergic airway inflammation?

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired.

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber Friedrich Horak, MD, Petra.

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial Annice Heratizadeh, MD, Thomas Werfel,

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? Ting Seng Tang, MBBS, Thomas.

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Tolerated wasp sting challenge improves health-related quality of life in patients allergic to wasp venom Jörg Fischer, MD, Martin Teufel, MD, Alexandra.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis Natalija Novak, MD,

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial Hendrik.

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

Sharon Seth, MD, David A. Khan, MD

What is an “eosinophilic phenotype” of asthma?

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

Jeffrey M. Harris, MD, PhD, Christopher R

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Cockroach allergens: Coping with challenging complexity

Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria Janine Gericke, PhD, Martin Metz, MD, Tatevik Ohanyan,

Real-life treatment of cholinergic urticaria with omalizumab

Autophagy: Nobel Prize 2016 and allergy and asthma research

Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber Thomas Werfel, MD, Annice Heratizadeh, MD, Margarete.

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis Karl-Christian Bergmann, MD, Pascal Demoly,

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down Eric D. Bateman, MD, Loretta Jacques, PhD,

Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria Katja Koch, Karsten Weller, MD, Andreas Werner,

Improvement of treatment-refractory atopic dermatitis by immunoadsorption: A pilot study Michael Kasperkiewicz, MD, Enno Schmidt, MD, PhD, Yvonne Frambach,

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD

Sonja A. Grundmann, MD, Pia B. Hemfort, MD, Thomas A

Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen- induced asthmatic reactions Emmerentia van Schalkwyk, MBChB, K. Strydom,

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Macrolide antibiotics and asthma treatment

A population-based questionnaire survey on the prevalence of peanut, tree nut, and shellfish allergy in 2 Asian populations Lynette Pei-Chi Shek, MRCP,

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD,

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Safety and efficacy of repeated monthly carboplatin desensitization

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele,

Natural history of cow’s milk allergy

The Editors’ Choice Journal of Allergy and Clinical Immunology

Primary prevention of asthma and allergy

Presentation transcript:

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase Marcus Maurer, MD, Sabine Altrichter, MD, Thomas Bieber, MD, Tilo Biedermann, MD, Matthias Bräutigam, PhD, Stefan Seyfried, PhD, Randolf Brehler, MD, Jürgen Grabbe, MD, Nicolas Hunzelmann, MD, Thilo Jakob, MD, Andreas Jung, MD, Jörg Kleine-Tebbe, MD, Martin Mempel, MD, Michael Meurer, MD, Kristian Reich, MD, Franziska Ruëff, MD, Knut Schäkel, MD, Kaushik Sengupta, BDS, MScD, Christian Sieder, MSc, Jan C. Simon, MD, Bettina Wedi, MD, Torsten Zuberbier, MD, Vera Mahler, MD, Petra Staubach, MD Journal of Allergy and Clinical Immunology Volume 128, Issue 1, Pages 202-209.e5 (July 2011) DOI: 10.1016/j.jaci.2011.04.038 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Organizational flow chart. Journal of Allergy and Clinical Immunology 2011 128, 202-209.e5DOI: (10.1016/j.jaci.2011.04.038) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 A, Change in UASs after 24 weeks of treatment. Difference between omalizumab and placebo = −9.9 (95% CI, 2.7-17.1). Population for analysis: intention-to-treat population. Analysis of covariance model: variables = baseline, center, and treatment. Least squares mean after adjusting the covariates, such as center, baseline value, and treatment group. B, Mean daily UAS. The standardized UAS over 24 weeks was significantly lower for omalizumab than placebo (P = .0002). Population for analysis: intention-to-treat population. Journal of Allergy and Clinical Immunology 2011 128, 202-209.e5DOI: (10.1016/j.jaci.2011.04.038) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Patients’ and investigator’s global assessment of symptoms at study’s end. Population for analysis: intention-to-treat population. Journal of Allergy and Clinical Immunology 2011 128, 202-209.e5DOI: (10.1016/j.jaci.2011.04.038) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Percentage improvement in quality of life (QoL). Population for analysis: intention-to-treat population. Journal of Allergy and Clinical Immunology 2011 128, 202-209.e5DOI: (10.1016/j.jaci.2011.04.038) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Reduction in concomitant and rescue medication use from baseline to week 24. Population for analysis: intention-to-treat population. Journal of Allergy and Clinical Immunology 2011 128, 202-209.e5DOI: (10.1016/j.jaci.2011.04.038) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E2 Percentage improvement in the quality-of-life subdomains of the Skindex questionnaire. Population for analysis: intention-to-treat population. Journal of Allergy and Clinical Immunology 2011 128, 202-209.e5DOI: (10.1016/j.jaci.2011.04.038) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E3 Percentage improvement in the subdomains of the Cu-Q2oL. Population for analysis: intention-to-treat population. Journal of Allergy and Clinical Immunology 2011 128, 202-209.e5DOI: (10.1016/j.jaci.2011.04.038) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions